Accueil › Maladies auto-immunes › Massachusetts › Boston
Essais cliniques pour Maladies auto-immunes à Boston, MA
13 études pour Maladies auto-immunes recherchent des participants dans et autour de Boston (dans un rayon d'environ 30 miles). Ouvrez une étude pour voir qui peut participer et comment contacter l'équipe.
Texte officiel de l'étude (anglais)
Vous recrutez pour une étude ? Mettez-la en avant en haut de cette page — $99 pour 30 jours →
Two Arm, Double-blind, Phase III Study Assessing Efficacy and Safety of Ianalumab Versus Placebo, in Participants With Sjögren's Disease With High Symptom Burden
Recrutement en coursPhase 3
- Tufts Medical Center, Boston
Testing an Immunotherapy Anti-cancer Drug, Nivolumab, for Advanced Cancers in Patients With Autoimmune Disorders, AIM-NIVO
Recrutement en coursPhase 1
- Massachusetts General Hospital Cancer Center, Boston
- Dana-Farber Cancer Institute, Boston
A Study of Mezagitamab in Adults With Chronic Primary Immune Thrombocytopenia
Recrutement en coursPhase 3
- Massachusetts General Hospital, Boston
RESET-Myositis: An Open-Label Study to Evaluate the Safety and Efficacy of CABA-201 in Subjects With Active Idiopathic Inflammatory Myopathy or Juvenile Idiopathic Inflammatory Myopathy
Recrutement en coursPhase 2/3
- Boston Children's Hospital - Accepting Young Adults and Juvenile Patients, Boston
A Follow-up Study of Mezagitamab in Adults With Chronic Primary Immune Thrombocytopenia
Recrutement en coursPhase 3
- Massachusetts General Hospital, Boston
RESET-SLE: A Phase 1/2 Open-Label Study to Evaluate the Safety and Efficacy of CABA-201 in Subjects With Active Systemic Lupus Erythematosus
Recrutement en coursPhase 1/2
- Tufts Medical Center, Boston
- Massachusetts General Hospital, Boston
- Boston Children's Hospital, Boston
- et 1 autres
RESET-MG: A Study to Evaluate the Safety and Efficacy of CABA-201 in Participants With Generalized Myasthenia Gravis
Recrutement en coursPhase 1/2
- Beth Israel Deaconess Medical Center, Boston
A Study of Mavorixafor in Participants With Congenital and Acquired Primary Autoimmune and Idiopathic Chronic Neutropenic Disorders Who Are Experiencing Recurrent and/or Serious Infections
Recrutement en coursPhase 3
- Boston Children's Cancer Center, Boston
A Study of Healthy Donor CD19-targeted Allogeneic CAR T Cells in Participants With Severe, Refractory Autoimmune Diseases
Recrutement en coursPhase 1
- Brigham And Womens Hospital, Boston
A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs)
Recrutement en coursÉtude observationnelle
- Tufts Medical Center, Boston
- Beth Israel Deaconess, Boston
- Dana Farber Cancer Institute, Boston
Study of Single Doses of SBT777101 in Subjects With Rheumatoid Arthritis
Recrutement en coursPhase 1
- Tufts University, Boston
- Massachusetts General Hospital, Boston
- Brigham and Women's Hospital, Boston
A Phase 1/2, Open-label, Safety and Dosing Study of Autologous CART Cells (Desmoglein 3 Chimeric Autoantibody Receptor T Cells [DSG3-CAART] or CD19-specific Chimeric Antigen Receptor T Cells [CABA-201]) in Subjects With Active, Pemphigus Vulgaris (RESET-PV)
Recrutement en coursPhase 1/2
- Brigham and Women's Hospital, Boston
Testimonials and Navigation in Rheumatology
Recrutement en cours
- Brigham Women's Hospital, Boston
Essais pour Maladies auto-immunes dans d'autres villes
- Houston, TX21 études
- Washington, DC19 études
- New York City, NY19 études
- Philadelphia, PA16 études
- Durham, NC15 études
- Los Angeles, CA12 études
- Chicago, IL12 études
- Dallas, TX9 études
- Cleveland, OH8 études
- Atlanta, GA8 études
- Milwaukee, WI8 études
- Portland, OR8 études
Autres études à Boston
- Cancer du sein111 études
- Cancer du poumon non à petites cellules90 études
- Cancer (tous types)86 études
- Cancer colorectal63 études
- Cancer métastatique63 études
- Cancer du poumon62 études
- Cancer de l'ovaire61 études
- Cancer de la prostate59 études
- Dépression52 études
- Cancer de l'endomètre50 études
- Insuffisance cardiaque44 études
- Leucémie aiguë myéloïde44 études
Source : ClinicalTrials.gov, données récupérées le 5 oct. 2026. Chaque étude définit ses propres critères d'éligibilité ; l'équipe de l'étude décide qui peut y participer.